Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proline henggliflozin in type 2 diabetes mellitus (24- and 52-week efficacy and safety)
CTR20170527Phase 3Completed
- Sponsor
- Hengrui Therapeutics
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of henagliflozin in type 2 diabetes mellitus (T2DM), sponsored by Hengrui Therapeutics. Started May 2017; status: completed.
02
Drugs
henagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20170527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170527.